Sodium Phosphate Cotransporter

钠磷协同转运蛋白 (Sodium phosphate cotransporters) 是一类膜蛋白,主要功能是调节钠 (Na+ 和磷酸盐 (PO43-) 的共转运。钠磷协同转运蛋白利用细胞内外钠离子的浓度梯度,通过主动转运机制帮助磷酸盐跨越细胞膜,对磷酸盐在体内的分布和利用起着核心作用。在哺乳动物中,这类转运蛋白主要由 SLC34 和 SLC20 两个家族成员构成。SLC34 家族包括 NaPi-IIa、NaPi-IIb 和 NaPi-IIc,主要在肾脏和小肠的上皮细胞顶膜位置表达,负责磷酸盐的再吸收和摄取,是磷酸盐跨上皮运输的限速步骤。SLC20 家族则包括 Pit-1和 Pit-2,这两种转运蛋白最初被发现时是作为逆转录病毒的受体,随后研究发现它们也能作为钠磷酸盐共转运蛋白,主要参与细胞内磷酸盐的调节,广泛表达于多种组织,如骨骼、肾脏和肠道等。在心血管系统中,Pit-1 可能参与高磷血症条件下的血管钙化过程。
钠磷酸盐共转运蛋白肾脏代谢疾病有关,如磷酸盐浪费症,是其潜在靶点[1][2]。

Sodium phosphate cotransporters are a type of membrane protein that primarily regulate the co-transport of sodium (Na+) and phosphate (PO43-). These transporters utilize the concentration gradient of sodium ions inside and outside the cell, employing an active transport mechanism to facilitate the movement of phosphate across the cell membrane, playing a central role in the distribution and utilization of phosphate within the body. In mammals, these transporters are primarily composed of members from the SLC34 and SLC20 families. The SLC34 family includes NaPi-IIa, NaPi-IIb, and NaPi-IIc, which are primarily expressed in the apical membrane of epithelial cells in the kidneys and intestines, responsible for the reabsorption and intake of phosphate, constituting the rate-limiting step in trans-epithelial phosphate transport. The SLC20 family includes Pit-1 and Pit-2, which were initially identified as receptors for retroviruses, but were later found to also function as sodium phosphate cotransporters, mainly involved in regulating intracellular phosphate levels and widely expressed in various tissues such as bones, kidneys, and intestines. In the cardiovascular system, Pit-1 may play a role in vascular calcification under conditions of hyperphosphatemia.
Sodium phosphate cotransporters are associated with renal metabolic diseases such as phosphate wasting syndrome, making them potential therapeutic targets[1][2].

By Effects: Inhibitor (2)
共 4种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
EOS789

EOS789 是一种口服有效的钠依赖性磷酸转运蛋白抑制剂,对人 NaPi-IIb、PiT-1、PiT-2 的 IC50 值分别为 6.8、1.5 和 1.7 μM,对大鼠 NaPi-IIb、PiT-1、PiT-2 的 IC50 分别为 3.9、1.9 和 1.7 μM,可抑制肠道磷吸收、增加粪便磷排泄、减少尿磷排泄、降低血清磷酸盐、FGF23 和成体甲状旁腺激素水平,并可改善异位胸主动脉钙化、肾脏损伤和高磷血症、抑制纤维化标志物的表达,因此可用于研究高磷血症及慢性肾脏病-矿物质骨病 (CKD-MBD)。

1628848-73-6
Inhibitor
99.14%
EOS789
LY3358966

LY3358966 是一种具有口服活性的钠依赖性磷酸盐协同转运蛋白 2b (NPT2b) 抑制剂,对人、小鼠和大鼠的 IC50 分别为 32.4 nM、43.9 nM 和 26.8 nM,可抑制 NPT2b 介导的肠道磷酸盐转运,降低磷酸盐向血浆的急性摄取并增加粪便磷酸盐排泄,可用于肾脏疾病的研究。

2187395-66-8
LY3358966
NaPi2b-IN-1

NaPi2b-IN-1 是一种钠依赖性磷酸盐转运蛋白 2b (NaPi2b) 抑制剂,IC50 为 64 nM,可抑制钠依赖性磷酸盐摄取并减少大鼠空肠袢中的肠道磷酸盐吸收,可用于高磷血症的研究。

1453116-06-7
Inhibitor
NaPi2b-IN-1
Lifastuzumab
利法妥珠单抗

Lifastuzumab 是一种人源化抗 NaPi2b IgG1 单克隆抗体,可通过 ADC 连接子与 monomethyl auristatin E (MMAE) (MS-Q21073) 偶联形成具有抗癌活性的抗体-药物偶联物 (ADC) Lifastuzumab vedotin (MS-V66882),用于研究非小细胞肺癌和卵巢癌,推荐同型对照为 Human IgG1 kappa, Isotype Control (MS-E04981)。

1615697-16-9
99.08%
利法妥珠单抗

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础